M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Study Of Yttrium-ibritumomab (Zevalin) For the Treatment Of Patients With Relapsed And Refractory Mantle Cell Lymphoma

Phase 2

Completed

Conditions: Lymphoma, Mantle-Cell

Interventions: Drug: Yttrium-ibritumomab (Zevalin)
Drug: Rituximab

First Posted Date: 2002-06-04

Last Posted Date: 2011-11-02

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 35

Registration Number: NCT00038623

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

A Phase IB Study Of Oral SCH 66336 Preoperatively In Patients With Head And Neck Squamous Cell Cancer

Phase 1

Completed

Conditions: Cancer of Head and Neck
Carcinoma, Squamous Cell

First Posted Date: 2002-06-03

Last Posted Date: 2018-10-30

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 37

Registration Number: NCT00038584

Locations: 🇺🇸
The University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States

Prophylactic Use of Filgrastim SD/01 in Patients With Hodgkin's Disease Receiving ABVD Chemotherapy

Phase 3

Completed

Conditions: Hodgkin Disease

Interventions: Drug: Filgrastim SD/01
Drug: Adriamycin
Drug: Bleomycin
Drug: Vinblastine
Drug: DTIC

First Posted Date: 2002-06-03

Last Posted Date: 2018-10-31

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 25

Registration Number: NCT00038558

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

A Phase II Study of Paclitaxel and Topotecan With Filgrastim-SD/01 Support For Relapsed and Refractory Aggressive Non-Hodgkin's Lymphoma

Phase 2

Completed

Conditions: Non-Hodgkin's Lymphoma

First Posted Date: 2002-06-03

Last Posted Date: 2018-10-30

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 25

Registration Number: NCT00038545

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Proteasome Inhibitor PS-341 Relapsed or Refractory B Cell Lymphomas Previously Treated With Chemotherapy

Phase 2

Completed

Conditions: Lymphoma, B-Cell

Interventions: Drug: PS341 (Bortezomib)

First Posted Date: 2002-06-03

Last Posted Date: 2018-10-31

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 60

Registration Number: NCT00038571

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Temozolomide and SCH66336 for Recurrent Glioblastoma Multiforme

Phase 2

Completed

Conditions: Glioblastoma Multiforme

First Posted Date: 2002-06-03

Last Posted Date: 2018-10-29

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 23

Registration Number: NCT00038493

Locations: 🇺🇸
UTMD Anderson Cancer Center, Houston, Texas, United States

Evaluation of the Addition of Herceptin to Standard Chemotherapy in the Neoadjuvant Setting for Operable Breast Cancer

Phase 3

Completed

Conditions: Breast Cancer

Interventions: Drug: Herceptin
Drug: Taxol
Drug: Fluorouracil
Drug: Cytoxan
Drug: Epirubicin

First Posted Date: 2002-05-31

Last Posted Date: 2012-07-20

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 74

Registration Number: NCT00038402

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Phase I Trial of Intramural Injection of DTI-015 for Recurrent Malignant Gliomas

Phase 1

Completed

Conditions: Glioma
Brain Neoplasms

Interventions: Drug: DTI-015

First Posted Date: 2002-05-31

Last Posted Date: 2018-10-31

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 39

Registration Number: NCT00038441

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Study of Vioxx and Radiation Therapy for Brainstem Glioma

Phase 1

Terminated

Conditions: Glioma
Brain Neoplasms

Interventions: Drug: Vioxx

First Posted Date: 2002-05-31

Last Posted Date: 2018-11-01

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 8

Registration Number: NCT00038389

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Phase II Study Of Roferon and Accutane For Patients With T-Cell Malignancies

Phase 2

Completed

Conditions: Lymphoma, T-Cell
Hematologic Neoplasms
Mycosis Fungoides

Interventions: Drug: Isotretinoin (Accutane)
Drug: Interferon Alpha

First Posted Date: 2002-05-31

Last Posted Date: 2018-10-29

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 56

Registration Number: NCT00038376

Locations: 🇺🇸
M. D. Anderson Cancer Center, Houston, Texas, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy